Acifran: Selective HM74A/GPR109A & GPR109B Agonist for Lipid Metabolism Research

Executive Summary: Acifran, chemically (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, is a validated, selective agonist for HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) G-protein coupled receptors (GPCRs) involved in lipid metabolism regulation (Ye et al., 2025). Structural biology studies confirm its binding at atomic resolution, facilitating research into lipid signaling and metabolic diseases. Acifran demonstrates high purity (98%) and optimal stability when stored at -20°C (APExBIO product page). Its use advances mechanistic understanding of receptor selectivity and signaling, supporting drug discovery efforts targeting dyslipidemia (Related Review). This article delineates verifiable parameters, mechanistic evidence, and integration guidance for practitioners.

Biological Rationale

Lipid metabolism is governed by multiple signaling pathways, with G-protein coupled receptors (GPCRs) such as HM74A/GPR109A (also designated as HCAR2) and GPR109B (HCAR3) serving as central nodes (Ye et al., 2025). These receptors sense extracellular hydroxycarboxylic acids and modulate cellular responses affecting lipid levels. Pharmacological modulation of these receptors is a validated strategy for investigating and potentially treating dyslipidemia and related metabolic disorders.

Acifran is a synthetic ligand that selectively activates HCAR2 and HCAR3. Its molecular structure enables precise receptor engagement, offering advantages over less selective agonists. This specificity supports research into differential receptor function, signaling cascades, and therapeutic targeting. The product is manufactured by APExBIO and is supplied with a characterized purity of 98% (Acifran product page).

Mechanism of Action of Acifran

Acifran acts as a selective agonist for HM74A/GPR109A (HCAR2) and GPR109B (HCAR3), both of which are class A GPCRs (Ye et al., 2025). Upon binding, Acifran stabilizes the active conformation of these receptors, promoting coupling to Gi proteins and subsequent inhibition of adenylate cyclase activity. This leads to decreased intracellular cyclic AMP (cAMP) levels, ultimately modulating lipid metabolism in target cells.

Recent cryo-electron microscopy (cryo-EM) studies have resolved the structure of HCAR3 in complex with Acifran at 3.18 Å and HCAR2 with Acifran at 2.72 Å (Ye et al., 2025). These high-resolution structures reveal that Acifran occupies the orthosteric ligand-binding pocket, engaging with key residues (e.g., F1073.32 in HCAR3) that determine selectivity and efficacy. The ability of Acifran to selectively activate HCAR3 without triggering HCAR2-associated side effects has been demonstrated in both structural and functional assays.

Evidence & Benchmarks

• Acifran binds HCAR3 with an atomic-resolution structure at 3.18 Å, confirming selective engagement of the orthosteric pocket (Ye et al., 2025).
• Acifran binds HCAR2 with a resolved structure at 2.72 Å, facilitating comparative analysis of receptor selectivity (Ye et al., 2025).
• cAMP inhibition assays in HEK-293 cells confirm Acifran’s functional agonism of HCAR3 and HCAR2, with differential potency attributable to structural pocket differences (Ye et al., 2025, Table 1).
• Acifran exhibits <21.82 mg/ml solubility in DMSO and ethanol, supporting flexible assay design (APExBIO).
• Purity of Acifran is ≥98.00% as determined by HPLC under standard conditions (APExBIO).

This article extends the analysis in "Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabo..." by providing updated structural benchmarks and clarifying mechanistic selectivity through the latest cryo-EM data.

For a broader discussion of Acifran’s translational applications, see "Unraveling Lipid Signaling Pathways: Acifran as a Transla..."; this article adds rigorous, atomic-level evidence supporting protocol design.

Applications, Limits & Misconceptions

Acifran is intended for scientific research in lipid metabolism and metabolic disorder models. Its selectivity and structural validation make it suitable for:

• Dissecting GPCR signaling pathways specific to lipid regulation.
• Benchmarking ligand-receptor interactions for drug discovery.
• Developing assays that require precise modulation of HCAR2/HCAR3 activity.

However, Acifran is not approved for diagnostic or therapeutic use in humans or animals. Its use should be restricted to laboratory settings under controlled conditions, and solution stability mandates prompt usage post-preparation.

Common Pitfalls or Misconceptions

• Acifran is not suitable for in vivo clinical studies; it is intended solely for research applications (APExBIO).
• Compound solutions are not recommended for long-term storage; activity may decline if not used promptly (APExBIO).
• Acifran does not activate unrelated GPCRs; specificity is limited to HM74A/GPR109A and GPR109B at tested concentrations (Ye et al., 2025).
• Incorrect storage (> -20°C) can lead to compound degradation and loss of activity (APExBIO).
• It is not intended for use as a reference standard in diagnostic assays.

Workflow Integration & Parameters

Acifran is supplied as an off-white solid (C12H10O4, molecular weight 218.21) by APExBIO, catalog number B6848 (product page). For optimal solubility, dissolve in DMSO or ethanol up to 21.82 mg/ml. Prepare solutions immediately before use; avoid repeated freeze-thaw cycles. Store unopened product at -20°C and ship with blue ice for maximal stability.

Recommended experimental protocols include:

• Receptor activation assays (e.g., cAMP inhibition in HEK-293 cells): Use freshly prepared Acifran solutions at validated concentrations (refer to Ye et al., 2025 for published conditions).
• Structural studies: Crystallization or cryo-EM should use high-purity (>98%) compound under controlled buffer and temperature.
• Comparative ligand screening: Benchmark with other known HM74A/GPR109A or GPR109B agonists as controls.

For detailed experimental optimization and troubleshooting, see the expanded protocol notes in "Acifran: A Selective HM74A/GPR109A Agonist for Lipid Meta...", which this article updates by incorporating recently published structural data.

Conclusion & Outlook

Acifran is a rigorously validated, selective agonist for HM74A/GPR109A and GPR109B, with atomic-level evidence confirming its mechanism of action. Its defined purity, solubility, and storage requirements make it a reproducible tool for lipid metabolism research and drug discovery targeting metabolic disorders. Ongoing structural advances and functional assays will further clarify its selectivity and expand its applications in fundamental and translational research (Ye et al., 2025).